Kim Blickenstaff - Tandem Diabetes CEO and President and Director

TNDM Stock  USD 35.41  0.11  0.31%   

CEO

Mr. Kim D. Blickenstaff is appointed as Executive Chairman of the Board of Tandem Diabetes Care, Inc. Mr. Blickenstaff has served as the Executive Chairman of our board of directors since March 2019, and on our board of directors since September 2007. Mr. Blickenstaff also previously served as our President and Chief Executive Officer from September 2007 to March 2019. Prior to joining our Company, Mr. Blickenstaff served as Chairman and Chief Executive Officer of Biosite Incorporated, or Biosite, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff previously served as a director of Medivation, Inc., a biotechnology company, from 2005 to 2016, until its acquisition by Pfizer, and as a director of DexCom, Inc., a provider of continuous glucose monitoring systems, from June 2001 to September 2007 since 2019.
Age 65
Tenure 5 years
Professional MarksMBA
Address 12400 High Bluff Drive, San Diego, CA, United States, 92130
Phone858 366 6900
Webhttps://www.tandemdiabetes.com
Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He holds a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

Tandem Diabetes Management Efficiency

The company has return on total asset (ROA) of (0.0963) % which means that it has lost $0.0963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5908) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to -0.29. In addition to that, Return On Assets is likely to drop to -0.25. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 28th of March 2024, Net Tangible Assets is likely to grow to about 531.2 M, while Return On Assets are likely to drop (0.25).
The company currently holds 415.67 M in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Tandem Diabetes Care has a current ratio of 4.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Tandem Diabetes until it has trouble settling it off, either with new capital or with free cash flow. So, Tandem Diabetes' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Tandem Diabetes Care sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Tandem to invest in growth at high rates of return. When we think about Tandem Diabetes' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

CEO Age

Paul KirchgraberLaboratory
59
Mark OrdanMednax Inc
65
John RatliffLaboratory
58
David CordaniCigna Corp
59
Deborah TannerLaboratory
52
James MDMednax Inc
62
Roger MedelMednax Inc
74
Gary HuffLaboratory
50
Helmy EltoukhyGuardant Health
44
Timothy WentworthCigna Corp
59
James BoyleLaboratory
58
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people. Tandem Diabetes Care (TNDM) is traded on NASDAQ Exchange in USA. It is located in 12400 High Bluff Drive, San Diego, CA, United States, 92130 and employs 2,400 people. Tandem Diabetes is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Tandem Diabetes Care Leadership Team

Elected by the shareholders, the Tandem Diabetes' board of directors comprises two types of representatives: Tandem Diabetes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tandem. The board's role is to monitor Tandem Diabetes' management team and ensure that shareholders' interests are well served. Tandem Diabetes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tandem Diabetes' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tom Fox, Chief Officer
Rebecca Robertson, Independent Director
David Esq, Transitional Advisor
Dick Allen, Chairman of the Board
Douglas Roeder, Independent Director
Leigh Vosseller, Senior Vice President - Finance
Rick Carpenter, Chief Officer
Elizabeth Gasser, Executive Officer
Brian Hansen, Chief Commercial Officer, Executive Vice President
Fred Cohen, Independent Director
Susan Morrison, Chief Admin. Officer
Lori Gildea, Vice President - Sales
Howard Greene, Independent Director
Ross Sylvia, VP Marketing
Christopher Twomey, Independent Director
Jordan MD, Chief Officer
Henry Anhalt, Independent Director
Edward Cahill, Independent Director
Lonnie Smith, Chairman of the Board
John Cajigas, CFO and Executive VP
David Berger, General Counsel
Jesse Treu, Independent Director
Richard Valencia, Independent Director
John Sheridan, COO and Executive VP
Kim Blickenstaff, CEO and President and Director
Robert Anacone, Chief Commercial Officer and Executive VP
Shannon Hansen, Privacy Legal

Tandem Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tandem Diabetes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Tandem Stock analysis

When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(3.43)
Revenue Per Share
11.509
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.